- Home
- ALLK vs MKZR Comparison
ALLK vs MKZR Comparison
Compare ALLK & MKZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLK
- MKZR
- Stock Information
- Founded
- ALLK 2012
- MKZR 2012
- Country
- ALLK United States
- MKZR United States
- Employees
- ALLK N/A
- MKZR N/A
- Industry
- ALLK Biotechnology: Pharmaceutical Preparations
- MKZR
- Sector
- ALLK Health Care
- MKZR
- Exchange
- ALLK Nasdaq
- MKZR Nasdaq
- Market Cap
- ALLK 23.0M
- MKZR 26.8M
- IPO Year
- ALLK 2018
- MKZR N/A
- Fundamental
- Price
- ALLK $0.33
- MKZR $1.14
- Analyst Decision
- ALLK Hold
- MKZR
- Analyst Count
- ALLK 3
- MKZR 0
- Target Price
- ALLK $2.00
- MKZR N/A
- AVG Volume (30 Days)
- ALLK 2.2M
- MKZR 34.9K
- Earning Date
- ALLK 05-08-2025
- MKZR 01-01-0001
- Dividend Yield
- ALLK N/A
- MKZR 16.81%
- EPS Growth
- ALLK N/A
- MKZR N/A
- EPS
- ALLK N/A
- MKZR N/A
- Revenue
- ALLK N/A
- MKZR $23,087,751.00
- Revenue This Year
- ALLK N/A
- MKZR N/A
- Revenue Next Year
- ALLK N/A
- MKZR N/A
- P/E Ratio
- ALLK N/A
- MKZR N/A
- Revenue Growth
- ALLK N/A
- MKZR 57.39
- 52 Week Low
- ALLK $0.22
- MKZR $1.05
- 52 Week High
- ALLK $1.56
- MKZR $5.50
- Technical
- Relative Strength Index (RSI)
- ALLK 60.40
- MKZR N/A
- Support Level
- ALLK $0.31
- MKZR N/A
- Resistance Level
- ALLK $0.33
- MKZR N/A
- Average True Range (ATR)
- ALLK 0.00
- MKZR 0.00
- MACD
- ALLK 0.00
- MKZR 0.00
- Stochastic Oscillator
- ALLK 78.50
- MKZR 0.00
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.